A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
for Atopic Dermatitis
Drug: Upadacitinib
83 locations incl. Birmingham
Sponsor: AbbVie
Sex: All·Age: 18 - 63
Code: NCT06389136·Phase 3·Recruiting